Stocks and Investing Stocks and Investing
Mon, May 23, 2022

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $110 on, May 23rd, 2022


Published on 2024-10-27 21:14:42 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $134 to $110 on, May 23rd, 2022.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Corinne Jenkins of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $10 on, Monday, May 9th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $25 on, Wednesday, February 16th, 2022
Contributing Sources